sinux overtrukne tabletter
bionorica se - ensianrod, kodriverblomst, skræppe urt, hyldeblomst, jernurt; tørekstrakter - overtrukne tabletter
klimadynon filmovertrukne tabletter
bionorica se - filmovertrukne tabletter
mucopret filmovertrukne tabletter
bionorica se - filmovertrukne tabletter
sinova overtrukne tabletter
bionorica se - overtrukne tabletter
sinova forte overtrukne tabletter
bionorica se - overtrukne tabletter
sinupret overtrukne tabletter
bionorica se - overtrukne tabletter
sinupret forte overtrukne tabletter
bionorica se - overtrukne tabletter
sinux overtrukne tabletter
bionorica se - overtrukne tabletter
skyrizi
abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - immunosuppressiva - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.
olumiant
eli lilly nederland b.v. - baricitinib - arthritis, reumatoid - immunosuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan anvendes som monoterapi eller i kombination med methotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.